Answers are grounded in this paper and cite their sources.
An orally active inhibitor of aldose reductase, 1,3-dioxo-1H-benz[de]-isoquinoline-2(3H)acetic acid (AY-22,284), prevented cataractous changes in cultured lenses exposed to high concentrations of galactose. When given orally, AY-22,284 markedly decreased the accumulation of polyols in the lenses and sciatic nerves of galactosemic rats and rats with streptozotocin-induced diabetes. In addition, treatment of galactosemic rats with AY-22,284 effectively suppressed the formation of cataracts.
No takes yet. Share an insight, caveat, or question.
Dvornik et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: